GB-115 Dosage Guide: Protocols, Calculator & Safety
Everything you need to know about GB-115 dosing: protocols, safety, and where to buy.
Half-Life
Not established in humans; the published rat pharmacokinetic work reported an absolute oral bioavailability of 4.65 percent for the crystalline substance and did not report a terminal half-life (PMID: 18457023)
Administration Routes
Quick Reconstitution Calculator
Calculate syringe units instantly
Syringe Draw
10.0 units
2500 mcg/ml · 0.100 ml draw
For laboratory research use only. This tool performs reconstitution math (concentration and syringe-unit conversion) and is not dosing guidance for humans or animals.
Dosing data for GB-115 is being researched. Check the compound page for the latest information.
Side Effects & Safety
Contraindications
None established in humans. Mechanism-based: the compound blocks central cholecystokinin receptors (PMID: 23113301), so concurrent drugs acting on that system are an untested interaction. It potentiated morphine analgesia in mice through supraspinal opioid mechanisms (PMID: 18239806), which makes combination with opioids a mechanism-based concern. It also has immunomodulating activity in mice, stimulating macrophage phagocytosis and the humoral immune response (PMID: 19145294), and suppressed an experimental inflammatory response in rodents (PMID: 22235394), neither of which has been characterized in people.
Frequently Asked Questions
What is the recommended GB-115 dosage?
Dosage for GB-115 varies by protocol. Consult a qualified healthcare provider.
How often should I take GB-115?
Administration frequency depends on the specific protocol. Consult current research literature.
Does GB-115 need to be cycled?
Cycling requirements depend on the protocol. Follow established research guidelines.
What are GB-115 side effects?
Preclinical safety work found no deaths after single oral administration at up to 6000 mg/kg in mice and 3500 mg/kg in rats, and no irreversible organ changes after six months of oral administration in male and female rats and rabbits; the compound showed no allergenic, immunotoxic or mutagenic activity and did not affect reproduction or antenatal and postnatal development of offspring, though it suppressed the inflammatory response to concanavalin A at the higher level tested (PMID: 20726348). Rats given the compound daily for 30 days showed no anxiety, aggression or convulsive signs on withdrawal, in contrast to diazepam (PMID: 21899090). In the single published clinical study the drug was described as safe and well tolerated, but that report provides no adverse event table in its abstract (PMID: 31626171). The Russian label for Rankvilon lists irritability, headache, nausea, diarrhea, drowsiness and sleep disturbance as adverse reactions of unknown frequency.
Where can I buy GB-115?
Compare 1 listings from 1 vendor on our price comparison page, starting from $59.99.
Free 2026 Peptide Cheat Sheet (PDF)
38 compounds and blends: vial sizes, BAC water volumes, dosing ranges and bloodwork markers.